Epicutaneous Immunotherapy (EPIT)

Dave Bloom - 2018/11/28

An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.

News Wire - 2018/10/23

"This submission represents a significant step forward for those families living with peanut allergy."

News Wire - 2018/09/12

Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.

Dave Bloom - 2018/03/23

Child’s food allergies have major impact on parents’ lives; majority of parents are willing to enroll their child in an immunotherapy clinical trial

Dave Bloom - 2017/11/20

The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.

Dave Bloom - 2017/03/22

The study received higher-than-expected patient demand.

Dave Bloom - 2017/03/08

Antibody targets trigger also implicated in other food allergies, atopic diseases, and asthma.

Dave Bloom - 2017/03/07

The study model used common packaged foods such as cookies, ice cream, and doughnuts as references.

Dave Bloom - 2016/10/25

The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.

Dave Bloom - 2016/06/13

The unique immune communication between skin and gastrointestinal tract can be used to generate long-lasting protection from food allergies.

12 Page 1 of 2

Tag: Epicutaneous Immunotherapy (EPIT)